What we do here
changes lives everywhere.

When you follow the science, one thing leads to another. A new insight takes a previous breakthrough further. And what we learn about cancer we turn against cancer.

Some of the scientists and patients continuing Dana‑Farber’s momentum of cancer discovery.

Dana-Farber shares patient stories which may include descriptions of actual medical results. Dana-Farber provides personalized care for each patient based on their unique needs; their experiences and results will vary.


What’s the story behind some of Dana-Farber’s most remarkable discoveries? This podcast series takes you deeper.


Explore the latest Dana-Farber advances in cancer medicine designed for medical professionals. 

Physician Resources

2nd Transatlantic Exchange Program focusses on Artificial Intelligence and Data Science in Oncology
  Hundreds of attendees (on-site and virtually) joined the 2nd Transatlantic Exchange program on Friday, 5 May 2023, in Paris, France. The day-long session focused on artificial intelligence (AI) and data science in oncology. The Masterclass pre...
Next-Generation Drug Improves Progression-Free Survival in Relapsed Chronic Lymphocytic Leukemia
A head-to-head clinical trial in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) has found that zanubrutinib, a next-generation BTK inhibitor, was more effective at preventing disease progr...
Dana-Farber research supports FDA approval of new therapy for certain patients with ovarian cancer
A novel antibody drug conjugate therapy whose clinical trial testing has been co-led by Ursula Matulonis, MD, of the Dana-Farber Cancer Institute has been granted accelerated approval by the U.S. Food and Drug Administration (FDA) on November 14 for ...
Symposium highlights 75 years of Dana-Farber science
Seventy-five years of research that has recast the understanding, treatment, and prevention of cancer took center stage at the Dana-Farber 2022 Scientific Symposium on Sept. 29. The all-day event featured nearly 20 presentations on topics such as the...
Three-drug combination slows progression of advanced kidney cancer
Patients treated with the three-drug combination had a 27% lower risk of progression or death compared to those on the two immunotherapy drugs. COSMIC-313 trial is the first phase 3 trial in metastatic renal cell carcinoma to use nivolumab plus ipili...
Dana-Farber Cancer Institute Celebrates 75th Anniversary
Commemoration to showcase decades of progress and leadership in cancer care and research Dana-Farber Cancer Institute is launching a year-long celebration of its 75th anniversary to highlight its history and progress in cancer care and transformative...